The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, ...
Objective: This study set out to identify the resource use and time commitment associated with treatment of anaemia with erythropoietic therapy, for both haematology/oncology clinics and patients.
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network Patients (N = 301) with ...
Value of caregiver ratings in evaluating the quality of life of patients with cancer. More than 500 community-based oncologists enrolled 2,342 patients with malignancies undergoing cytotoxic ...
BRIDGEWATER, N.J., March 7 /PRNewswire/ -- Ortho Biotech Products, L.P. today modified prescribing information for PROCRIT(R) (Epoetin alfa), following guidance from the U.S. Food and Drug ...
The FDA has approved Pfizer’s epoetin alfa-epbx (Retacrit), a biosimilar to epoetin alfa (Epogen), marking the first biosimilar approval of 2018 and the first biosimilar erythropoiesis-stimulating ...
Please provide your email address to receive an email when new articles are posted on . This week, the FDA released MedWatch alerts regarding the safety of three oncologic therapeutic agents. Chromic ...
Fixed-Dose Phosphate Binder Schedules May Be Less than Ideal Researchers confirmed higher dose conversion ratios in Taiwanese patients with stable hemoglobin. For Asian hemodialysis (HD) patients with ...
Credit: Shutterstock Newly released safety data also show that roxadustat is associated with reduced cardiovascular risks compared with epoetin alfa. WASHINGTON—Roxadustat is superior to epoetin alfa ...
Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Additional data are needed regarding the effectiveness and ...
The Hematology and Oncology Clinics of three US medical centres - Dartmouth-Hitchcock Medical Center (Lebanon, NH), Pacific Shores Medical Group (Long Beach, CA) and South Carolina Oncology Associates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback